FrancophonIA/ELRC3.0 huggingface dataset:
English: Further information on Neulasta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Nadaljnje informacije o zdravilu Neulasta so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Neulasta?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Neulasta?
English: Neulasta received a marketing authorisation valid throughout the EU on 22 August 2002.
Slovenian: Za zdravilo Neulasta je bilo 22. avgusta 2002 izdano dovoljenje za promet, veljavno po vsej EU.
English: The European Medicines Agency decided that Neulasta's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Neulasta večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Other information about Neulasta
Slovenian: Druge informacije o zdravilu Neulasta
English: An overview of Neulasta and why it is authorised in the EU
Slovenian: Pregled zdravila Neulasta in zakaj je odobreno v EU
English: What benefits of Neulasta have been shown in studies?
Slovenian: Kakšne koristi zdravila Neulasta so se pokazale v študijah?
English: What is Neulasta and what is it used for?
Slovenian: Kaj je zdravilo Neulasta in za kaj se uporablja?
English: The most common side effect with Neulasta (which may affect more than 1 in 10 people) is pain in the bones.
Slovenian: Najpogostejši neželeni učinek zdravila Neulasta (ki se lahko pojavi pri več kot 1 bolniku od 10) je bolečina v kosteh.
English: As for all medicines, data on the use of Neulasta are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Neulasta stalno spremljajo.
English: Why has Neulasta been approved?
Slovenian: Zakaj je bilo zdravilo Neulasta odobreno?
English: Neulasta has been studied in two main studies involving 467 patients with breast cancer who were being treated with chemotherapy.
Slovenian: Zdravilo Neulasta so proučevali v dveh glavnih študijah, v katerih je sodelovalo 467 bolnic z rakom dojke, ki so jih zdravili s kemoterapijo.
English: What are the risks associated with Neulasta?
Slovenian: Kakšna tveganja so povezana z zdravilom Neulasta?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Neulasta have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Neulasta upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: The company that markets Neulasta will ensure that patients or carers using the medicine are provided with an alert card explaining how to use the injection device that delivers the medicine.
Slovenian: Podjetje, ki trži zdravilo Neulasta, bo zagotovilo, da bodo bolniki ali skrbniki, ki uporabljajo zdravilo, prejeli opozorilno kartico, na kateri bo razloženo, kako uporabljati pripomoček za injiciranje zdravila.
English: Side effects reported with Neulasta are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Neulasta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Neulasta can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.
Slovenian: Predpisovanje in izdaja zdravila Neulasta je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem rakavih obolenj ali krvnih bolezni.
English: Neulasta is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Slovenian: Zdravilo Neulasta se daje v obliki enkratnega odmerka v jakosti 6 mg, ki se injicira pod kožo vsaj 24 ur po koncu vsakega ciklusa kemoterapije (zdravljenja z zdravili proti raku).
English: For more information about using Neulasta, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Neulasta glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: In both studies, the effectiveness of a single injection of Neulasta was compared with multiple daily injections of filgrastim during each of four chemotherapy cycles.
Slovenian: V obeh študijah so enkratno injiciranje zdravila Neulasta primerjali z večkratnimi dnevnimi injiciranji filgrastima med vsakim od štirih ciklusov kemoterapije.
English: The active substance in Neulasta, pegfilgrastim, consists of filgrastim, which is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Slovenian: Učinkovina v zdravilu Neulasta, pegfilgrastim, je sestavljena iz filgrastima, ki je zelo podoben človeški beljakovini, imenovani granulocitne kolonije spodbujajoči faktor (G-CSF).
English: It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever).
Slovenian: Zdravilo se daje za skrajševanje trajanja nevtropenije in preprečevanje febrilne nevtropenije (nevtropenije, ki jo spremlja povišana telesna temperatura).
English: In both studies, the patients had severe neutropenia for around 1.7 days during their first chemotherapy cycle.
Slovenian: V obeh študijah je nevtropenija pri bolnicah trajala približno 1,7 dneva med prvim ciklusom kemoterapije.
English: For the full list of side effects and restrictions with Neulasta, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Neulasta glejte navodilo za uporabo.
English: Neulasta is effective at reducing the duration of severe neutropenia during chemotherapy and its side effects were considered manageable.
Slovenian: Zdravilo Neulasta je učinkovito pri skrajševanju hude nevtropenije med kemoterapijo, njegovi neželeni učinki pa veljajo za obvladljive.
English: Neulasta is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Slovenian: Zdravilo Neulasta ni namenjeno uporabi pri bolnikih z vrsto krvnega raka, imenovano kronična mieloična levkemija, ali mielodisplastičnimi sindromi (obolenji, pri katerih nastajajo velike količine nenormalnih krvnih celic, ki se lahko razvijejo v levkemijo).
English: Neulasta was as effective as filgrastim in reducing the duration of severe neutropenia.
Slovenian: Zdravilo Neulasta je bilo pri skrajšanju hude nevtropenije enako učinkovito kot filgrastim.
English: How does Neulasta work?
Slovenian: Kako zdravilo Neulasta deluje?
English: Neulasta is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.
Slovenian: Neulasta je zdravilo, ki se uporablja pri bolnikih z rakom za pomoč pri nevtropeniji (zmanjšanem številu nevtrofilcev, vrste belih krvnih celic), ki je pogost neželeni učinek pri zdravljenju raka, zaradi katerega pa so bolniki dovzetnejši za okužbe.
English: How is Neulasta used?
Slovenian: Kako se zdravilo Neulasta uporablja?
English: In Neulasta, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Slovenian: V zdravilu Neulasta je filgrastim pegiliran (vezan na kemično snov, imenovano polietilenglikol).
English: You may require medical attention.
Slovenian: Mogoče boste potrebovali zdravniško pomoč.
English: Date of latest renewal: 15 February 2016
Slovenian: Junij2011 Datum zadnjega podaljšanja: 15. februar 2016
English: Frequency categories are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Slovenian: Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti ).
English: • if you have a low body weight.
Slovenian: • če imate majhno telesno težo.
English: • if you are allergic to rivastigmine or any of the other ingredients of this medicine (listed in section 6).
Slovenian: • če ste alergični na rivastigmin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Angina pectoris
Slovenian: Angina pektoris
English: • Seeing things that are not there (hallucinations)
Slovenian: • Vidna zaznava nečesa, česar v resnici ni tam (halucinacije)
English: Patients without visual hallucinations hallucinations
Slovenian: Bolniki brez vidnih halucinacijami halucinacij
English: If you have not taken Rivastigmine Actavis for more than three days, do not take the next dose until you have talked to your doctor.
Slovenian: Če zdravila Rivastigmin Actavis niste jemali že več kot tri dni, ne vzemite naslednjega odmerka, dokler se ne pogovorite s svojim zdravnikom.
English: The capsules are packed in blisters available in three different pack sizes (28, 56 and 112 capsules) and capsule containers of 250 capsules, but these may not all be available in your country.
Slovenian: Kapsule so pakirane v pretisnih omotih, ki so na voljo v treh različnih velikostih pakiranj (28, 56 in 112 kapsul) in vsebnikih za kapsule po 250 kapsul, vendar morda v vaši državi niso na voljo vsa navedena pakiranja.
English: • High blood pressure
Slovenian: • Visok krvni tlak
English: However, rivastigmine may be used in this patient population and close monitoring is necessary.
Slovenian: Vendar se v tej populaciji bolnikov lahko uporabi in potrebno je natančno spremljanje.
English: Protein binding of rivastigmine is approximately 40 %.
Slovenian: Rivastigmin se veže na beljakovine v približno 40 %.
English: Absolute bioavailability after a 3 mg dose is about 36 %±13 %.
Slovenian: Absolutna biološka uporabnost po odmerku 3 mg je okrog 36 % ± 13 %.
English: • if you suffer from trembling.
Slovenian: • če imate težave s tresenjem.
English: • Urinary incontinence (inability to retain adequate urine)
Slovenian: • Urinska inkontinenca (nezmožnost zadrževanja urina)
English: At least 4 points improvement on ADASCog with no worsening on CIBIC-Plus and PDS *p<0.05, **p<0.01, ***p<0.001
Slovenian: Izboljšanje za vsaj 4 točke pri ADAS-Cog brez poslabšanja pri CIBIC-Plus in PDS *p<0.05, **p<0.01, ***p<0.001
English: Patients with mild dementia dementia (MMSE 10-17)
Slovenian: Bolniki z blago demenco demenco (MMSE 10-17)
English: • Slow and fast heartbeat
Slovenian: • Počasen in hiter srčni utrip
English: If this applies to you, tell your doctor and do not take Rivastigmine Actavis.
Slovenian: Če kaj od navedenega velja za vas, povejte svojemu zdravniku in ne jemljite zdravila Rivastigmin Actavis.
English: No clinical data on exposed pregnancies are available.
Slovenian: Na voljo ni kliničnih podatkov od nosečnic, ki so bile izpostavljene zdravilu..
English: Most cases of accidental overdose have not been associated with any clinical signs or symptoms and almost all of the patients concerned continued rivastigmine treatment 24 hours after the overdose.
Slovenian: Večina primerov nenamernega prevelikega odmerjanja ni bila povezana z nikakršnimi kliničnimi znaki ali simptomi in skoraj vsi ti bolniki so nadaljevali zdravljenje z rivastigminom24 ur po prevelikem odmerjanju.
English: - Blisters (Al/PVC): 28, 56 and 112 hard capsules.
Slovenian: - Pretisni omot (Al/PVC): 28, 56 in 112 trdih kapsul.
English: Elderly population
Slovenian: Starejši ljudje
English: Your doctor will tell you what dose of Rivastigmine Actavis to take.
Slovenian: Zdravnik vam bo povedal, kakšen odmerek zdravila Rivastigmin Actavis morate jemati.
English: An initial dose of 0.03 mg/kg intravenous atropine sulfate is recommended, with subsequent doses based on clinical response.
Slovenian: Priporočamo začetni odmerek 0,03 mg/kg atropinijevega sulfata intravensko, nadaljnji odmerki pa naj temeljijo na kliničnem odzivu.
English: • Feeling tired or weak
Slovenian: • Občutek utrujenosti ali šibkosti
English: Elevated liver function tests
Slovenian: Zvišani jetrni funkcijski testi
English: Administration of rivastigmine with food delays absorption (tmax) by 90 min and lowers Cmax and increases AUC by approximately 30 %.
Slovenian: Jemanje rivastigmina skupaj s hrano upočasni absorpcijo (tmax) za 90 minut in zmanjša Cmax ter poveča AUC za okrog 30 %.
English: Hypersensitivity to the active substance, to other carbamate derivatives or to any of the excipients listed in section 6.1.
Slovenian: Preobčutljivost na zdravilno učinkovino, druge derivate karbamata ali katero koli pomožno snov, navedeno v poglavju 6.1.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Slovenian: Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravilana na nacionalni center za poročanje, ki je naveden v Prilogi V.
English: Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative StudyClinician's Global Impression of Change).
Slovenian: Učinkovitost so dokazali z uporabo dveh neodvisnih lestvic, s katerima so bolnike ocenjevali v rednih presledkih med 6mesečnim obdobjem zdravljenja, kot kaže Preglednica 5 spodaj: ADAS-Cog, merilo kognitivne zmogljivosti, in globalno merilo ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change /Kooperativna študija Alzheimerjeve bolezni-globalni klinični vtis sprememb).
English: Hard capsule (Capsule).
Slovenian: trda kapsula (kapsula)
English: Not known (frequency cannot be estimated from the available data) • Allergic reaction where the patch was used, such as blisters or skin inflammation
Slovenian: Pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov) • alergijske reakcije na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože
English: C-rivastigmine, renal elimination was rapid and essentially complete (>90 %) within 24 hours.
Slovenian: C, je bilo ledvično izločanje hitro, saj se je dejansko ves (> 90 %) izločil v 24 urah.
English: Rivastigmine belongs to a class of substances called cholinesterase inhibitors.
Slovenian: Rivastigmin pripada skupini snovi, ki se imenujejo zaviralci holinesteraze.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Slovenian: • Redno posodobljena poročila o varnosti zdravila (PSUR) Imetnik dovoljenja za promet z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
English: Rivastigmine Actavis should not be given at the same time as other medicines with similar effects to Rivastigmine Actavis.
Slovenian: Zdravila Rivastigmin Actavis ne smete jemati sočasno z drugimi zdravili, ki imajo podobne učinke kot zdravilo Rivastigmin Actavis.
English: Do not use this medicine after the expiry date which is stated on the carton, blister or capsule container after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake EXP, pretisnem omotu ali vsebniku za kapsule.
English: What Rivastigmine Actavis is and what it is used for
Slovenian: Kaj je zdravilo Rivastigmin Actavis in za kaj ga uporabljamo
English: In vitro, this metabolite shows minimal inhibition of acetylcholinesterase (<10 %).
Slovenian: In vitro kaže ta presnovek zelo majhno stopnjo zaviranja acetilholinesteraze (< 10 %).
English: The European Medicines Agency has waived the obligation to submit the results of studies with rivastigmine in all subsets of the paediatric population in the treatment of Alzheimer's dementia and in the treatment of dementia in patients with idiopathic Parkinson's disease (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z rivastigminom za vse podskupine pediatrične populacije glede zdravljenja Alzheimerjeve demence in zdravljenja demence pri bolnikih z idiopatsko Parkinsonovo boleznijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS.
Slovenian: Klinično pomembno izboljšanje v teh študijah je bilo opredeljeno a priori kot izboljšanje pri ADAS-Cog za vsaj 4 točke, izboljšanje pri CIBIC-Plus ali vsaj desetodstotno izboljšanje pri PDS.
English: • Dehydration (losing too much fluid)
Slovenian: • Dehidracija (čezmerna izguba tekočine)
English: A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer's disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Slovenian: Rezultati populacijske farmakokinetične analize so pokazali, da pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) uporaba nikotina za 23% poveča očistek rivastigmina pri peroralnem odmerjanju rivastigmina v kapsulah v odmerkih do 12 mg/dan.
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Slovenian: Druga zdravila in zdravilo Rivastigmin Actavis Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
English: If you take more Rivastigmine Actavis than you should If you accidentally take more Rivastigmine Actavis than you should, inform your doctor.
Slovenian: Če ste vzeli večji odmerek zdravila Rivastigmin Actavis, kot bi smeli Če nehote vzamete več zdravila Rivastigmin Actavis, kot bi smeli, obvestite svojega zdravnika.
English: How to store Rivastigmine Actavis Contents of the pack and other information
Slovenian: Shranjevanje zdravila Rivastigmin Actavis Vsebina pakiranja in dodatne informacije
English: • Take Rivastigmine Actavis twice a day, in the morning and evening, with food.
Slovenian: • Zdravilo Rivastigmin Actavis jemljite s hrano dvakrat na dan, zjutraj in zvečer.
English: • Trembling or feeling confused
Slovenian: • Tresenje ali občutek zmedenosti
English: These events led to the discontinuation of rivastigmine in some cases (e.g. discontinuations due to tremor 1.7 % on rivastigmine vs. 0 % on placebo).
Slovenian: Zaradi teh težav so v nekaterih primerih prekinili zdravljenje z rivastigminom (npr. z rivastigminom 1,7 % prekinitev zaradi tremorja v primerjavi z 0 % pri placebu).
English: • Severe confusion
Slovenian: • Huda zmedenost
English: - Capsule containers (HDPE) with LDPE caps: 250 hard capsules.
Slovenian: - Vsebnik za kapsule (HDPE) s pokrovčkom LDPE: 250 trdih kapsul.
English: • Tell your caregiver that you are taking Rivastigmine Actavis.
Slovenian: • Povejte svojemu negovalcu, da jemljete zdravilo Rivastigmin Actavis.
English: Cardiac arrhythmia (e.g. bradycardia, atrio-ventricular block, atrial fibrillation and tachycardia)
Slovenian: Srčne aritmije (npr. bradikardija, atrioventrikularni blok, atrijska fibrilacija in tahikardija)
English: Other side effects seen with rivastigmine transdermal patches and which may occur with the hard capsules:
Slovenian: Drugi neželeni učinki, ki so jih opažali pri uporabi transdermalnih obližev rivastigmina in bi se lahko pojavili tudi pri uporabi trdih kapsul:
English: In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
Slovenian: Pri bolnikih z Alzheimerjevo demenco ali z demenco zaradi Parkinsonove bolezni določene celice v možganih odmrejo, to pa povzroči znižano koncentracijo nevrotransmiterja acetilholina (to je snov, ki omogoča živčnim celicam, da komunicirajo med seboj).
English: If you have to undergo surgery whilst taking Rivastigmine Actavis, tell your doctor before you are given any anaesthetics, because Rivastigmine Actavis may exaggerate the effects of some muscle relaxants during anaesthesia.
Slovenian: Če morate v času jemanja zdravila Rivastigmin Actavis na operacijo, morate obvestiti zdravnika, da jemljete zdravilo Rivastigmin Actavis, preden dobite kakršnokoli anestezijo, ker lahko zdravilo Rivastigmin Actavis med anestezijo poveča učinke nekaterih mišičnih relaksantov.
English: If adverse reactions persist, the daily dose should be temporarily reduced to the previous welltolerated dose or the treatment may be discontinued.
Slovenian: Če neželeni učinki vztrajajo, moramo dnevni odmerek začasno zmanjšati na odmerek, ki ga je bolnik poprej še dobro prenašal, oziroma prekiniti zdravljenje.
English: What Rivastigmine Actavis is and what it is used for What you need to know before you take Rivastigmine Actavis How to take Rivastigmine Actavis Possible side effects
Slovenian: Kaj je zdravilo Rivastigmin Actavis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Rivastigmin Actavis Kako jemati zdravilo Rivastigmin Actavis Možni neželeni učinki
English: Clinical studies in dementia associated with Parkinson's disease The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Slovenian: Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo, so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom kontrolirani osnovni študiji in njeni 24-tedenski odprti podaljšani fazi.
English: • Too much saliva and dehydration
Slovenian: • Čezmerno slinjenje in dehidracija
English: What you need to know before you take Rivastigmine Actavis
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Rivastigmin Actavis
English: If you find you have forgotten to take your dose of Rivastigmine Actavis, wait and take the next dose at the usual time.
Slovenian: Če ste pozabili vzeti zdravilo Rivastigmin Actavis Če ugotovite, da ste pozabili vzeti odmerek zdravila Rivastigmin Actavis, počakajte in ob običajnem času vzemite naslednji odmerek.
English: PHARMACEUTICAL FORM AND CONTENTS 28 hard capsules
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA 28 trdih kapsul
English: Rivastigmine Actavis is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Slovenian: Zdravilo Rivastigmin Actavis uporabljamo za zdravljenje odraslih bolnikov z blago do zmerno hudo Alzheimerjevo demenco, to je napredujoča bolezen možganov, ki postopoma prizadene spomin in intelektualne sposobnosti ter vpliva na vedenje bolnika.
English: Manufacturer Specifar S.A 1, 28 Octovriou str. 123 51 Ag. Varvara Athens
Slovenian: Izdelovalec Specifar S.A 1, 28 Octovriou str. 123 51 Ag. Varvara Atene